🇺🇸 FDA
Patent

US 10350162

Methods and compositions for oral administration of exenatide

granted A61KA61K31/202A61K31/22

Quick answer

US patent 10350162 (Methods and compositions for oral administration of exenatide) held by Oramed Ltd. expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Oramed Ltd.
Grant date
Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/202, A61K31/22, A61K38/26, A61K38/56